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Summary Recently, cytokine gene transfer into tumour cells has been shown to mediate tumour regression in animal models via
immunomodulation. Consequently, a number of clinical protocols have been developed to treat cancer patients with cytokine gene-modified
tumour cells. Here, we report the results of a clinical phase trial using forthe first time autologous, interleukin 7 gene-modified tumour cells for
vaccination of ten patients with disseminated malignant melanoma. Melanoma cells were expanded in vitro from surgically removed
metastases, transduced by a ballistic gene transfer technique and were then injected after in vitro irradiation s.c. at weekly intervals. Clinically,
there was no major toxicity except for mild fever, and no major clinical response towards vaccination was observed. Eight of ten patients
completed the initial three s.c. vaccinations and were eligible for immunological evaluation. Post vaccination, peripheral mononuclear cells
(PBMCs) were found to contain an increased number of tumour-reactive proliferative as well as cytolytic cells, as determined by a limiting
dilution analysis. In three of six patients, the frequencies of anti-melanoma cytolytic precursor cells increased between 2.6- and 28-fold. Two of
these patients showed a minor clinical response. Analysis of the autologous tumour cell vaccines regarding IL-7 secretion after gene transfer,
HLA class and class 11 cell surface expression, secretion of immunosuppressive mediators (TGF-,1, IL-10) and various melanoma-associated
tumour antigens revealed a very diverse expression profile. In conclusion, vaccination using gene-modified autologous melanoma cells
induced immunological changes in a group of advanced, terminally ill patients. These changes can be interpreted as an increased anti-tumour
immune response. However, immunological modulation was most pronounced in patients in good physical condition. Therefore, patients with
minimal tumour load or minimal residual disease might preferentially benefit from tumour cell vaccination in further studies. In order to evaluate
the effects of the cytokine gene-modified tumour cell vaccines more precisely, an antigenically better defined vaccine is needed.
Keywords: gene transfer; cytolytic T lymphocyte; ballistic particle transfer; limited dilution transfer
Incidence of malignant melanoma has increased dramatically
world-wide over the last few decades. Standard forms of cancer
therapy, such as surgery, radiation and chemotherapy, although
effective in certain types ofcancer, fail to cure affected patients. In
its advanced stage, melanoma has a high mortality because of its
high resistance to conventional therapies (Ahmann et al, 1989; Ho
and Sober, 1990; Schadendorfet al, 1994, 1995).
A number of clinical observations in human malignant
melanoma underline the potential importance of the immune
response in this disease (Old, 1981; Oettgen and Old, 1991;
Ferrone, 1994; Mackensen et al, 1994). It is believed that the
immune attack ofinfiltrating lymphocytes against melanoma cells
may be responsible for the occurrence of spontaneous, partial or
complete melanoma regression and for the concomitant destruc-
tion of melanocytes in benign lesions, leading to clinical
phenomena, such as halo nevi, uveitis and vitiligo in melanoma
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patients. These observations, together with anecdotal and clinical
reports of tumour regression after bacterial infections, application
of bacterial vaccines or more specific immune interventions,
suggest that melanoma is a good model for the evaluation of the
various strategies ofimmune therapy (Old, 1981; Oettgen and Old,
1991; Ferrone, 1994; Mackensen et al, 1994). Recently, cytolytic
T lymphocytes (CTL), which recognize and destroy tumour cells,
have been isolated from blood- or from tumour-infiltrating
lymphocytes of melanoma patients by numerous investigators
(reviewed by Boon et al, 1994; Houghton, 1994). Furthermore, it
has been demonstrated that such T lymphocytes are capable of
mediating impressive tumour regression in vivo (Kawakami et al,
1994; Robbins et al, 1994).
The pioneering work of Tepper and co-workers (1989) showed
that tumour cells were rejected after transfection of the IL-4 gene
in an animal tumour model. In addition, Fearon and colleagues
(1990) demonstrated that cytokines, after gene transfer, can bypass
some ofthe co-stimulatory signals needed for T-cell priming so as
to cause tumourrejection. Consequently, applications ofnumerous
cytokine genes, including IL-7, have been tested in such animal
models for their capacity to inhibit tumour growth and metastasis
formation (reviewed by Horsch et al, 1993; Colombo and Forni,
1994; Vieweg and Gilboa, 1995).
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Table 1 Patient characteristics and DTH reactivity [autologous melanoma cells and Multitest Merieux skin test (sum of total diameter given in mm/no. of
reactive antigens)] before and after third vaccination
Patient DTH reactivity DTH reactivity
(Multitest Merieux) (autologous
tumour cells)
No. Age/ Sites of Previous therapies HILA type Karnofsky Before gene After third Before gene After third
sex metastases index therapy vaccination therapy vaccination
1 51F LN, lungs, skin, Surgery, IFN + IL-2, Al, A2, B60, B62, Cw3, >70 13.5/3 11.5/3 0 0
brain DTIC + IFN DR4, DR13
2 63F LN, skin, lungs, Limb perfusion, All, A32, B7, B52, Cw5, >70 21.5/3 16/4 0 0
liver DTIC, surgery DR1, DR2
3 52M LN, liver, lungs Vindesine + IFN, A2, B44, B51, Cw5, Cw8, <70 2.5/1 6.0/2 0 0
radiation DR4, DR13
4 29M LN, skin, lungs Surgery, radiation A2, A32, B7, B60, Cw3, >70 32/4 NA 0 NA
Cw7, DR4
5 83M LN, skin, liver, Surgery, DTIC + IFN A3, A19, B15, B39, Cw3, >70 4.0/1 6.0/2 0 0
spleen, brain Cw7, DR7, DR9
6 26M Skin, lungs, DTIC + DDP + BCNU ND <70 0.0/0 NA 0 NA
bone, LN IFN + IL-2, radiation
7 33F LN, skin, liver, Vindesine + IFN, IL-2, ND <70 0.0/0 0.0/0 0 0
lung, gut DTIC, DDP
8 48F LN, lungs Surgery, IL-2 + IFN, A2, All, B22, B75, Cw1, >70 18/3 3.0/1 0 0
DTIC Cw3, DR1, DR15
9 52F Skin, LN, IFN + IL-2, DTIC, A2, A24, B8, B62, Cw4 <70 3/1 0.0/0 0 0
Fotemustine
10 52M Skin, LN, lungs, Vindesine + IFN, A2, A9, B44, Cw4, DR7, >70 13/2 8.0/3 0 0
brain DTIC, DDP, DR11
ND, not done; NA, not applicable; 0, no DTH reactivity; LN, lymph node.
IL-7 was originally identified as a factor required for the prolif-
eration and maturation ofpre-B cells, and this cytokine has subse-
quently been found to augment the growth and cytotoxicity of T
cells (Hickman, 1990). In vitro, IL-7 is used to support APC-
induced T-cell priming with a higher specificity than in the
presence of IL-2 (Kos and Millbacher, 1992; Celis et al, 1994).
Compared with other cytokines, anti-tumour response induced by
paracrine-secreted IL-7 seems to be more strictly dependent on T
cells (Hock et al, 1993; Miller et al, 1993), although IL-7 is able to
induce LAK activity (Alderson et al, 1990; Bohm et al, 1994), to
enhance NK activity (24) and to generate tumoricidal activity in
monocytes (Alderson et al, 1991). In a comparative study in a
mouse tumour model using a murine plasmocytoma cell line, the
IL-7-secreting gene-modified tumour cells showed, in contrast to
other cytokine-secreting tumour cells, a dependency of CD4+ T
cells on early tumour rejection, whereas CD8+ T cells were
required for long-term tumour eradication (Hock et al, 1993).
Based on the successful animal studies using gene-modified
tumour cells, various clinical protocols for the treatment ofhuman
cancer, predominantly using cytokine gene modifications, have
been initiated in recent years. Indeed, only three reports on clinical
gene therapy trials dealing with non-haematological neoplasms
have been published as yet (reviewed by Culver, 1996).
A vaccination therapy using gene-modified autologous tumour
cells is especially feasible in melanoma and is thought to present
potentially all individual tumour antigens to the host immune
system. To investigate the autologous vaccination approach, we
manipulated autologous melanoma cells to overexpress IL-7 using
a mammalian expression plasmid vector system and a ballisto-
magnetic gene transfer technique (Schadendorf et al, 1995b). A
first clinical phase I trial was carried out to evaluate the feasibility
and the clinical toxicity of such an approach. Furthermore, we
report here for the first time on the modulation of immune
response in a subset of patients with far advanced, metastatic
melanoma after immunization with an IL-7 gene-modified, auto-
logous tumour cell vaccine.
MATERIALS AND METHODS
Patient selection
According to the protocol published previously (Schadendorfetal,
1995b), accessible melanoma metastases were removed surgically,
and melanoma cells were expanded in vitro (as described below)
and transduced by ballistic gene transfer (see below). After
magnetic enrichment of IL-7 gene-modified tumour cells and,
after irradiation, patients were immunized s.c. at weekly intervals
using multiple aliquots of the cell preparations. Patients were
required to have histologically proven metastatic melanoma,
adequate hepatic and renal function (bilirubin < 50 Rtmol 1-'; serum
creatinine < 266 ,umol 1-1) and needed to have at least one prior
unsuccessful systemic treatment including chemotherapy,
immunomodulators or a combination ofboth. A life expectancy of
more than 8 weeks was required. Furthermore, patients with any
severe cardiac or psychiatric disease as well as concurrent acute
infection with hepatitis virus or HIV were excluded. All partici-
pants gave informed consent before enrolling in the study, as
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Table 2 Cytokine gene transfer for treatment of malignant melanoma: scheme of immunological and clinical investigations
Number of days after gene transfer
Procedure -7-0 1 8 15 29 36 50 64
Vaccinationa
Autologous melanoma cells plus gene + + + + +
encoding interleukin 7
Venepuncture
Blood samples for analysis of: + + +
lymphocyte proliferation; natural killer and
lymphokine-activated killer cell activity;
fluorescence-activated cell-sorting analysis;
and cytotoxic T-cell precursor analysis
Immunological tests
Delayed-type hypersensitivity skin tests for + + +
common recall antigens and autologous
melanoma cells (irradiated)
Skin biopsiesb
Biopsies tested for presence of melanoma + + +
cells, lymphocytic infiltration and other
irradiated cells
Clinical evaluation
Chest radiography, ultrasound (lymph nodes, + + +
abdomen) and computerized tomography (brain)
aVaccination can be continued at 4-week intervals, depending upon clinical response. bSkin biopsy is only made if a clinical response has been observed.
required by the Virchow Clinic Institutional Ethical Review Board
and according to the Declaration of Helsinki. Treatment was
carried out at the Department of Dermatology, Virchow Clinic,
Berlin. Patient recruitment started in December 1994, and the
study was closed in March 1996. Ten patients were enrolled and
basic data are summarized in Table 1.
Treatment
Within 1 week before vaccination, medical history was taken, and
the following baseline studies were performed: a physical exami-
nation, haematological testing (haemoglobin, haematocrit, leuco-
cyte and platelet count), blood chemistry panel and urinalysis.
Blood was also taken for immunological testing. Delayed-type
hypersensitivity skin tests were performed with the commercially
available Multitest Merieux test, with cell lysates from autologous
melanoma cells and with PBMCs before vaccination and at
5-week intervals thereafter. Chest radiography and computerized
topographic scans of brain, chest and abdomen were performed
unless previously obtained within 8 weeks. Eligible patients
received three vaccinations at weekly intervals as shown in Table
2, according to the published protocol (Schadendorf et al, 1995b).
In most instances, the vaccine preparation was split into equal
aliquots ofabout 106 cells each and administered s.c. intradermally
in close proximity to the regional lymph nodes of each extremity.
Comprehensive immunological screening, haematological testing
and a crude clinical assessment (physical examination, chest radi-
ography, ultrasound examination of the abdomen) was carried out
before the fourth vaccination at day 36. A complete clinical and
immunological screening similar to the initial work-up was carried
out during treatment week 10 (day 64) for final evaluation.
Patients were followed up until death.
Clinical response and toxicity criteria
Although a clinical response could not be expected and was not the
primary aim of this phase I trial, tumour sites were evaluated by
physical examinations and scans at 6-weekintervals. Standard defi-
nitions ofmajor (complete orpartial) objective responses were used
(Schadendorfet al, 1994). A minorresponse (MR) was defined as a
25-50% decrease oflesion lasting at least 1 month, or a more than
50% decrease of lesions lasting less than a month. Stable disease
(SD) was defined as less than a 25% change in size with no new
lesions developing for 6 weeks. Survival was measured from diag-
nosis of first distant metastasis or start of vaccination using gene-
modified autologous tumour cells. Adverse effects were recorded
using common WHO toxicity criteria.
Preparation of autologous melanoma cells
Tumour specimens were collected from patients with advanced
melanoma undergoing procedures either as a part ofthe diagnostic
work-up or for palliative treatment of their disease. Solid tumour
specimens from lymph nodes, cut is or subcutis were placed
immediately after removal into RPMI 1640 (Gibco, Eggenstein,
Germany). Adjunct non-melanoma-containing tissue was removed
as completely as possible by scalpel or scissors, and tumours were
subsequently cut into pieces. After passing the pieces through a
steel mesh with a pore size of 25 jum, the cells were washed twice
and cultured in complete RPMI 1640 medium supplemented with
20% fetal calf serum (FCS; Seromed, Berlin, Germany). For
vaccination, passages 2-10 were used. On histological and
immunocytochemical examinations of cytospin preparations of
these cultured cells, they were confirmed as being melanoma cells
by a S-100 staining index of> 95%.
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Polymerase chain reaction (PCR)
PCR was carried out with reversely transcribed cDNA generated
from all melanoma cell lines as described previously (Schadendorf
et al, 1996). Briefly, the following primer sequences were used:
Tyr-l, TTG GCA GAT TGT CTG TAG CC and Tyr-2, AGG CAT
TGT GCA TGC TGC TT, which generate a 284-bp DNA amplifi-
cate specific for tyrosinase; Tyr-3, GTC TTT ATG CAA TGG
AAC GC and Tyr-4, GCT ATC CCA GTA AGT GGA CT, which
generate a second 207-bp DNA amplificate specific for tyrosinase;
MAGE1-3, CTT GCC TCC TCA CAG AG and MAGE1-5, TTG
CCG AAG ATC TCA GGA A, which generate a 407-bp DNA
amplificate specific for the MAGE-1 gene; MAGE3-5, TGG AGG
ACC AGA GGC CCC C and MAGE3-3, GGA CGA TTA TCA
GGA GGC CTG C, which generate a 714-bp DNA amplificate
specific for the MAGE-3 gene; pMEL175, AGA TCC TGC AGG
CTG TGC and pMEL173, CAA TGG GAC AAG AGC AGA,
which generate a 540-bp DNA amplificate specific for the
gplOO/pMEL17 gene; MART1-5, ACT GCT CAT CGG CTG
TTG and MARTI-3, TCA GCC ATG TCT CAG GTG, which
generate a 265-bp DNA amplificate specific for the MART-
I/Melan-A gene.
Determination of IL-10 and TGF-i1
Immunosuppressive mediators, such as IL-10 (Immunotech,
Hamburg, Germany) and TGF-fi1 (Genzyme, Cambridge, MA,
USA), released by melanoma cells used for vaccination were
performed by quantitative immunoenzymometric kits. Then,
2 x 105 melanoma cells in 2 ml of complete medium were seeded
in 24-well plates at 37°C in a 5% carbon dioxide atmosphere for
24 h. Cytokine levels were determined in the supematants. The
sensitivity was 0.05 ng ml' for TGF-fi1 and 5 pg ml' for IL-10,
respectively, as indicated by the manufacturers.
Maintenance of cell cultures
Newly established human melanoma cell lines of patients were
grown in complete medium (RPMI 1640 supplemented with 10%
FCS, 2 mm glutamine (Gibco) and 100 U ml' penicillin/strepto-
mycin (Seromed). Cultures were maintained at 37°C in an atmos-
phere of 5% carbon dioxide in air. The NK-sensitive cell line
K562, autologous EBV-immortalized B cell lines and autologous
melanoma cells, all grown in complete medium, were used as
further target cells in the immunological assays. The T-cell lines
were generated and maintained in T-cell medium (RPMI
containing 10% pooled human AB serum (Sigma, Deisenhofen,
Germany), 25 mM HEPES buffer, 2 mM glutamine, 100 U ml'
penicillin, 100 gg/ml-' streptomycin). After 4 weeks of limited
dilution (LD) culture, growth ofgenerated T cell lines was further
supported by addition of autologous inactivated EBV-immortal-
ized B cell lines. For the LDH release assay, a separate
medium consisting of RPMI 1640 without phenol red (Seromed,
Berlin, Germany) was used supplemented with 2 mM glutamine,
100 U ml' penicillin, 100 ,ug ml-' streptomycin and 3% FCS
(medium B).
Ballistomagnetic gene transfer for expression of
plasmids into melanoma cells
The full-length human IL-7 gene was cloned into a eukaryotic
expression vector pRc/CMV (Invitrogen, Heidelberg, Germany)
and entirely sequenced before use as described (Schadendorfet al,
1995b). For gene transfer, the newly developed ballistomagnetic
vector system, which can efficiently transfer nucleic acids and
other biomolecules into the nuclei, up to 1 x 108 cells were used,
which allowed us to obtain >90% of pure transfected cells in less
than 1 h. Briefly, the ballistomagnetic vector system is a two-step
procedure, i.e. the actual transfer of nucleic acids together with
superparamagnetic particles into the nuclei of many cells,
followed by a magnetic isolation of transfected cells. At the first
step, a suspension of colloidal gold (0.9 mg, 1.6 ptm, BioRad;
Germany) was pipetted onto each of seven particle carrier
membranes (purchased as macro-carrier from BioRad) and
allowed to sediment. After removal of the supernatant, the gold
particles were resuspended in a mixture of three parts of an
aqueous solution of DNA and two parts of a suspension of
colloidal superparamagnetic particles of 30-nm diameter
(Miltenyi, used as purchased) and were allowed to dry onto the
particle carrier membranes at room temperature. The accelerating
system for ballistic transfer is based on the biolistic PDS-1000/He
apparatus (1550 psi rupture disk, 20 inches Hg of vacuum,
BioRad). After ballistomagnetic transfer, cells were immediately
resuspended in 5 ml of phosphate-buffered saline (PBS) and
transferred onto a high-gradient magnetic separation column
(capacity 3 x 107 cells, type AS, Miltenyi), which was prepared
according to the supplier's protocol. An aliquot ofthe cell suspen-
sion was kept for reference (unsorted fraction). The cell suspen-
sion was passed through the column, followed by a washing step
with 3 ml ofPBS. After removal ofthe column from the magnetic
separator, the retained cells were flushed back to the top of
the column. Finally, the column was removed from the separator
and eluted with 5 ml of PBS (magnetic fraction). Recovered cells
were sedimented at 400g at 4°C for 7 min and resuspended
in tissue culture medium. Cells were incubated under culture
conditions for 24 h.
IL-7 secretion after gene transfer and irradiation
The following day, gene-modified melanoma cells were irradiated
with 100 Gray in a small volume. Cells were subsequently
detached from flasks by mechanical scraping and ice-cold PBS,
washed three times with sterile PBS and finally counted and resus-
pended with 5 x 106 gene-modified melanoma cells per ml. An
aliquot of 106 cells was transferred to a single well of a 24-well
plate (Nunc) for determining cytokine secretion after 24 h, using
an IL-7 ELISA (EIAKIT PerSeptive Diagnostics, Cambridge,
MA, USA). Detection range was between 10 and 200 pg ml'
according to the manufacturer's instructions. The biological
activity of the IL-7-containing supematant was analysed and
confirmed with a bioassay that used the IL-7-dependent IxN/2b
pre-B-cell line as described (Namen et al, 1988).
Immunological studies
Delayed-type hypersensitivity (DTH)
DTH tests were performed 2 days before the first vaccination and
during weeks 6 and 12 of treatment. Two preparations were used
each time, one consisting of an autologous melanoma cell lysate
and the other consisted ofautologous peripheral blood mononuclear
cell (PBMC) lysate as anegative control. The melanoma test prepa-
ration was prepared from autologous cells of each patient, starting
with 4 x 106 suspended, mitomycin-inactivated (45 min, 37°C)
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primary melanoma cells. After PBS washings, cells were lysed by
three cycles of freeze-thawing. Aliquots of 1.3 x 106 cell equiva-
lents were stored in 0.3 ml of PBS per tube at -80°C. The autolo-
gous PBMC lysate was prepared after separation of leucocytes by
ficoll centrifugation using the same procedures as described above
for melanoma cells. For DTH testing, 1 x 106 cell equivalents were
injected intradermally into the forearm. In parallel, a commercially
available recall DTH test (Multitest Merieux), was administered on
the opposite forearm. A positive skin test reaction was defined as
>5 mm diameter induration after 48 h.
Preparation ofautologous lymphocytes
PBMCs were isolated from heparinized venous blood of patients
by Ficoll-Hypaque (Biorad, Berlin, Germany) density centrifuga-
tion, washed two times with PBS and either resuspended in
complete culture medium (see target cells) or cryopreserved in
liquid nitrogen in the presence of more than 50% FCS. EBV-
immortalized B cell lines were used as autologous targets and as
feeder cells supporting T-cell growth. Immortalized B cell lines
were generated using a standard method (Blumberg et al, 1987)
using B95-8 marmoset cell line supernatant containing EBV.
Limiting dilution microcultures
To estimate changes in the frequency of tumour-reactive T cells as
well as tumour-specific cytolytic T-lymphocyte (CTL) precursors
in the peripheral blood, we used a limiting dilution analysis (LDA)
method, described by Coulie et al (1992) with minor modifications.
Briefly, cryopreserved PBMCs obtained before vaccination and
2 weeks after the third vaccination were seeded at limiting
dilutions in microcultures of 96 V-bottom microwells (Nunc, Ros-
kilde; Denmark) with 1 x 104 mitomycin-inactivated autologous
melanoma cells in the presence of 20 U ml-1 IL-2 and 200gl of
medium. Cell viability was required to be above 85% by trypan
blue exclusion, and cell counts were performed by two independent
investigators (PM, YS). At least 48 microcultures were set up for
each dilution ofPBMCs (10 000, 5000, 2500, 1250, 625, 312 cells
per well). On day 14, the cells were transferred into flat-bottom
microwells (Nunc). Microcultures were restimulated on days 7, 14
and 21 with 1 x 104 inactivated melanoma cells per well with
20 U ml-' IL-2 in either 100 ,ul of fresh medium/V-bottom well or
200 ,l of fresh medium/flat-bottom well. Cultures were washed
once and resuspended in 200gl of medium B. Three aliquots of
60,l were transferred into U-bottom microwells (Nunc) to test
their lytic activity in a LDH release assay.
Determination ofproliferative T-cell response
Proliferative T-cell response could be assessed only by micro-
scopic inspection because of the limited number of cells needed
for cytolytic assessment. Therefore, all LDA microcultures were
scored semiquantitatively at day 25 for proliferative response. The
following criteria to identify visible clones in LDA microcultures
were used: 0, no cell clusters, less than 15% ofbottom covered by
proliferating cells; +++, bottom of well covered more than 50%
with proliferating PMBC-derived cells; ++, bottom of well
covered between 25% and 50%; +, bottom of well covered
between 15% and 25% by proliferating blood cells.
Determination ofcytotoxicity ofresponderlymphocytes
upon co-culture with autologous melanoma cells using the
LDH release assay
All microculture wells were analysed regarding cytolytic activity
using the LDH release assay. The LDH release assay is a colori-
metric enzyme release test that showed a good correlation to the
radioactive 5'Cr release assay (Decker et al, 1988). Here, it was
used to measure the lytic activity generated in the LDA microcul-
tures against non-adherent target cells (e.g. the NK-sensitive cell
line K562) and autologous melanoma cells. For further T-cell line
characterization, lyric activity was also tested against autologous
EBV-immortalized B cells.
The assay was performed using a commercially available detec-
tion kit for LDH (Boehringer Mannheim, Mannheim, Germany)
that detects released LDH by reduction of a tetrazolium salt (INT)
to a water-soluble red formazan salt mediated by NAD+/NADH
and lactate/pyruvate. Briefly, effector cells obtained from LDA
Table 3 Number of gene-modified cells used for each vaccination administered into multiple injection sites (number given in parentheses). IL-7 release of
,vaccination batch' of cells after irradiation (100 Gy) given as pg of IL-7 ml-' 10-6 cells day-'. Total number of gene-modified melanoma cells and total IL-7 dose
levels given were calculated after third vaccination
Patient Number and IL-7 release of cells used for vaccination
Number First dose IL-7 release Second IL-7 release Third dose IL-7 release Total number of Total IL-7 dose
'first dose' dose 'second dose' 'third dose' cells administered received
1 1 X 107 (3) 1031 1 x 107 (4) 746 1 x 107 (4) 927 3x 107 27 040
2 1 x 106(2) 713 2x106(2) 310 3x106(2) 202 6x106 1939
3 2x 106(2) 511 2x106(3) 701 1 x106(2) 668 5x106 3092
4 2 x 106 (2) 231 4 x 106 (3) 182 Not given NA 6 x 106 1190
5 2 x 106 (2) 406 1.5 x 107 (4) 424 6 x 106 (4) 402 2.3x 107 9584
6 5 x 105 (2) ND Not given NA Not given NA NA NA
7 1 x 106 (2) 900 1 x 106 (2) 1162 1 x 106 (2) 1560 3 x 106 3622
8 3.2 x 106 (3) 885 1 x 106 (2) 1131 1.1 x 107 (4) 485 1.5 x 107 8814
9 5 x 105 (1) 1170 2 x 106 (2) 604 3 x 106 (3) 490 5.5 x 106 3263
10 4x 106 (4) 515 2.7x 106 (3) 380 4x 106 (4) 635 1.1 x 107 5628
ND, not done; NA, not applicable.
British Joumal ofCancer (1998) 77(11), 1907-1916 0 CancerResearch Campaign 19981912 P Moller et al
Table 4 Characterization of melanoma cell vaccines used for the immunization
Patient Patients' surface markers (MFI) TGF-pl release Expression of tumour antigens (RT-PCR)
no.
HLA-A,B,C HLA-A2 HLA-DR HLA-DQ (ng ml-' 1 5 cells day-') Tyr-1/2 Tyr-3/4 gplOO MART-1 MAGE-1 MAGE-3
1 64.5 1.1 1.6 1.5 0.33 +/- + + + - -
2 126.4 ND 70.4 3.6 0.47 + + + +/- - +
3 71.1 10.4 1.0 1.0 0.85 ND
7 158.2 ND 274.5 1.2 0.41 + + - - + +/-
8 67.9 9.4 1.0 1.0 0.37 + + + +/- - -
9 44.6 4.4 1.0 1.0 0.74 - - +/- - - -
10 46.9 3.7 5.1 1.1 0.66 + + + +/- - +
MFI (mean fluorescence index) = fluorescence of specific stained cells/fluorescence of negative control staining; ND, not done; -, not detectable;
+, specific amplification; +/-, questionable, at the detection level.
microcultures were washed and split into three aliquots of 60 .t
and transferred to 96-well U-bottom microplates (Nunc). Then,
5 x I03 target cells (autologous melanoma or K562 cells) in 100 lt
per well medium B were added (designed as 'A experimental').
Plates were incubated for 6 h at 37°C in 5% humified carbon
dioxide. After centrifugation at 250g for 7 min, supematants were
transferred to corresponding wells of 96 flat-bottom microwells
(Nunc), and 100 gl of test kit solution (catalyst and dye solution)
was added to each well. After incubation for 30 min at room
temperature, the absorbance (A) at 492 nm wavelength was
determined using an ELISA reader (Titertek Multiscan MCC/340,
Meckenheim, Germany). Medium B served as background
control. The specific lysis was calculated according to the formula:
Lysis (%) =
(A experimental - A effector cell spontaneous)
- A target cell spontaneous
A target cell total - A target cell spontaneous
'A effector cell spontaneous' and 'A target cell spontaneous' were
determined from the test solution, which contains a 60-gl aliquot
of the LDA microculture without target cells plus medium B; 'A
target cell total' (maximal release) was obtained after treatment
with 1% triton X 100 (Sigma); 'A target cell spontaneous' ranged
between 10% and 20% oftotal release.
Analysis of T-cell reactivity in microcultures
All microcultures with an LDH release exceeding the mean spon-
taneous release from target cells (T) (measured in 12 control wells)
by at least three standard deviations were considered to be cytolyt-
ically positive. The statistical method of precursor cell frequency,
95% confidence intervals and P-values indicative of single-hit
kinetics were determined by a computer program based on
published methods (Taswell, 1981) kindly provided by Dr Heeg
(Muinchen, Germany).
Flowcytometry
One-colour analysis was performed on an EPICS XL (Coulter,
Krefeld, Germany) as described (Bohm et al, 1994). Aliquots of
4 x 105 trypsinized melanoma cells in PBS containing 0.1%
sodium azide were incubated with antibodies for 30 min at 4°C.
Staining of cell surface markers ofmelanoma cells was performed
using unlabelled antibodies detecting HLA-A,-B,-C, HLA-DR,
HLA-DQ, ICAM- 1 (all obtained from Immunotech, Hamburg,
Germany) and HLA-A2 (Clone BB7.2; a gift from Dr Coulie,
Brussels, Belgium) and the respective isotype control antibodies in
combination with a FITC-labelled goat anti-mouse Ig antibody
(Immunotech).
Statistical analysis
Statistical significance of the data obtained from the cytoxicity
assays and IL-4 measurements were calculated using a SPSS
computer package. A modified Wilcoxon signed-rank test and a
Mann-Whitney U-test were used.
RESULTS
Clinical assessment of the course of disease
Ten patients (Table 1) were enrolled in the study. All patients
suffered from advanced metastatic melanoma, with the mean
disease-free interval from excision of the primary tumour to the
first distant metastasis amounting to 24.5 months (not shown). As
all patients had received various conventional oncological treat-
ment regimens, an additional 9.6 months had elapsed on average
before vaccination was started (not shown). Approximately 50%
(n = 19) of melanoma metastases received could be sufficiently
expanded in vitro. Vaccination treatment could be initiated
between 2 weeks and 3 months after surgical removal of the
metastases in ten patients with the remaining nine patients having
died meanwhile. Patients received between 5 x 105 (minimal
required number) and 1.5 x 107 autologous, IL-7 gene-modified
melanoma cells per vaccination as shown in Table 3. IL-7 secre-
tion of gene-modified cells varied between 182 and 1560 pg ml
10-6 cells during 24 h, with the total number of gene-modified
cells administered ranging between 3 x 106 and 3 x 107 and a
calculated total IL-7 dose between 1.19 and 27.04 ng (Table 3).
Preclinical studies demonstrated that after irradiation of gene-
modified melanoma cells with 100 Gy, transfected cells increased
IL-7 secretion for 1-3 days in vitro, and subsequently production
of IL-7 was decreasingly detectable over 2 weeks (Finke et al,
1997). Eight of ten patients received the first three immunizations
and were evaluable in week 5. One patient (no. 6, DB) died after
the first vaccination as a result of disease progression and
unrelated to the vaccination. A second patient (no. 4, EB) refused
further immunization after the second injection (Table 3). No
major clinical response (CR, PR) was observed in any patient.
Four patients (no. 1, no. 2, no. 3, no. 5) showed stable disease and
two a mixed response (no. 8, no. 10). These six patients received a
fourth vaccination, but further immunization was terminated atthe
next hospital visit in all cases because of tumour progression.
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Table 5 Frequency analysis of tumour-reactive lymphocytes in PBMCs
Patient Proliferative activity Total lytic activitya
no.
B A B A
1 1/3987 1/3677 1/8959 1/8345
2 1/3458 1/3032 1/323413 1/140 119
3 1/4671 1/3325 1/59 173 1/47 595
7 1/24 058 1/9883 b b
8 1/8351 1/1452 1/135 065 1/5381
9 c c c c
10 1/3970 1/3342 1/29 176 1/7114
aLytic activity against autologous melanoma cells or K562. bNo lytic cells
were generated. cDid not follow single-hit kinetics with P-values > 0.1.
B before vaccination; A after vaccination.
Table 6 LD cultures with lytic activity against autologous melanoma cellsa
and frequency analysis (f) of anti-melanoma lytic cells in PBMCs
Patient no. B f A f
1 13 (4) 1/59 758 25 (7) 1/23 187
3 3 (0) b 2 (0) b
8 4 (3) 1/159 700 79 (20) 1/5740 (1/36 659)
10 2 (0) b 10 (3) b
aNumber of LD cultures with lytic activity either against autologous melanoma
only or against autologous melanoma and K562 in one LD culture. In
parentheses: LD cultures and frequency, respectively, with specific lytic
activity (lytic activity against autologous melanoma cells only). bDid not follow
single-hit kinetics, with P-values > 0.1. fFrequency in PBMCs
Patients died on average 4 months after initiation of vaccination
with IL-7 gene-modified tumour cells, demonstrating their poor
physical condition overall. Immunologically, responsive patients
(no. 1, no. 8, no. 10) survived for 7.3 months on average (3, 10, 9
months respectively). Patient no. 8 showed an 8-month stabiliza-
tion of disease with cutaneous metastases appearing and disap-
pearing in short intervals.
Immune status
Skin reactivity
Delayed-type hypersensitivity (DTH), i.e. T-cell reactivity with
common recall antigens, such as bacterial antigens, tetanus toxoid,
etc., as determined by the Multitest Merieux and reflecting the
overall immunological status ofthe patients, was already dramati-
cally reduced in five patients (no. 3, no. 5, no. 6, no. 7, no. 9)
before therapy. In addition, four of the six patients had a
Karnofsky index below 70 (Table 1). No specific DTH reactivity
using autologous melanoma cells was observed in any patient at
any time point after intradermal injection ofautologous melanoma
cell or peripheral blood cell lysates (Table 1).
Characterization of vaccines
To evaluate possible interactions between immune effecter cells
and melanoma cells used as tumour vaccines, we characterized the
autologous melanoma cells regarding the expression of cell
surface markers (HLA-A,-B,-C, HLA-A2, HLA-DR, HLA-DQ
and ICAM-1) using FACS, the release of immunosuppressive
mediators (IL-10 and TGF-41) using ELISA and tumour antigens
known to be recognized by T cells (tyrosinase; gplOO, MART-1,
MAGE-1 and MAGE-3) using RT-PCR. All melanoma cells used
for vaccination demonstrated high reactivity with MAb recog-
nizing HLA-A,-B,-C (Table 4), as they did with ICAM-1 (not
shown). Peripheral blood lymphocytes (PBIs) from patients no. 1,
no. 3, no. 8, no. 9 and no. 10 were typed HLA-A2 positive (Table
1), whereas patient no. 1 showed a loss of HLA-A2 expression on
her melanoma cells that could not be up-regulated by IFN-y (not
shown). HLA-DR expression on melanoma cells was detected in
two patients (no. 2, no. 7; Table 4). TGF-1 secretion by tumour
cells varied between 0.33 to 0.85 ng ml 10-5 cells day-' (Table 4),
whereas IL-10 secretion was not detectable in all cell lines (not
shown). Expression of tumour antigens was determined by RT-
PCR and demonstrated the presence of tyrosinase (primers Tyr-
1/2, Tyr-3/4) and gplOO in five of six melanoma lines analysed.
MART-l/Melan-A was detected in one patient's tumour cells (no.
1) abundantly and in three others at the detection level. MAGE-1
was not expressed in cell lines tested, whereas MAGE-3 was
detected in patients' no. 2, no. 7 and no. 10 melanoma cells.
Interestingly, melanoma cells of patient no. 8, who demonstrated
the highest increase of the anti-melanoma response in LD cultures
after vaccination (Table 6), secreted only small amounts of TGF-
P1, expressed strongly the HLA-A2 and three known tumour anti-
gens known to be recognized by T cells in a HLA-A2-dependent
fashion (Table 4).
Frequency analysis oftumour-reactive lymphocytes
Our aim was to determine the changes ofthe precursorfrequencies
of tumour-reactive lymphocytes in PBMCs before and after the
vaccinations. This could be realized in most patients by setting up
limiting dilution (LD) microcultures to obtain mixed lymphocyte
tumour cultures (MLTCs) in a statistically sufficient number and
distribution for a mathematical evaluation. As a side-product, we
generated several T cell lines at the end ofthe LD culture periods.
Quantitative results of lytic clones and semiquantitative results
of proliferative clones from PBMCs obtained before the first and
after the third vaccination could be determined in seven patients
after co-culture with autologous melanoma cells over 25 days in
vitro. Proliferative T-cell response could be determined only by
microscopic inspection as the cell number was too low to perform
thymidine incorporation and cytolytic assessment in parallel. Six
patients were evaluable for frequency analysis of tumour-reactive
proliferation and cytotoxicity (Table 5). Four out of six evaluable
patients showed an increase in the frequency of proliferative
and/or cytolytic precursor lymphocytes after vaccination. Two
patients had a significant increase oftumour-reactive proliferation
in responder lymphocytes (no. 7, 4.1-fold; no. 8, 5.75-fold;
P < 0.01). An increase in lytic activity directed against autologous
melanoma cells could be detected in three patients (Table 6; no. 1,
no. 8, no. 10). In patients no. I and no. 8, the precursor frequency
analysis of anti-melanoma lyric activity as well as of tumour-
reactive, proliferative lymphocyte cultures could be calculated,
and they demonstrated a 2.6-fold (no. 1) and a 28-fold (no. 8)
increase of lytic activity against autologous melanoma cells in
peripheral blood upon immunization (Figure 1). We could not
perform a target cell competition with the NK-sensitive target cell
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Figure 1 Precursor analysis of proliferative and cytolytic anti-melanoma lytic lymphocytes. Increase in frequency of proliferative and cytolytic anti-melanoma
lytic lymphocytes in PBMCs of patient no. 1 (A and B) and patient no. 8 (C and D). Limited dilution analysis was performed as described in Materials and
methods with PBMCs obtained before (U) and two weeks after the third (O) vaccination by LDH test
line K562 to abolish the NK-like activity as the LDH release assay
was used for cytolytic testing. However, cytotoxicity against NK-
sensitive cell line K562 and melanoma cells were analysed in
parallel. By analysing LD cultures with lytic activity against autol-
ogous melanoma cells but without cytotoxicity against K562, an
increase of the melanoma-specific cytotoxic T cell precursor
(pCTL) frequency of more than fourfold for patient no. 8 was
observed (Table 6).
Further analysis of 34 cytolytic T cell lines of three patients
revealed that 32 out of 34 T cell lines exhibited specific reactivity
against autologous melanoma cells without cross-reactivity
against autologous EBV B cells. Preliminary analysis of seven out
of seven CTL lines obtained from patients no. 1 and no. 8 demon-
strated a HLA class I-dependent recognition of the melanoma
cells, as could be shown by blocking experiments using the HLA
class I-neutralizing MAb W6/32 (kindly provided by Dr P Coulie).
Furthermore, in patient no. 1, recognition of tumour cells by T
cells was HLA-B/HLA-C and not HLA-A2 restricted, as HLA-A2
was lost (Table 4), and HLA-A2-blocking antibody BB7.2 had no
effect on T-cell-mediated cell lysis.
Adverse effects and toxicity
Vaccinations were well tolerated by all patients without any signs
of toxicity. No erythema, swelling or induration was detectable in
any ofthe patients. Mild fever (grade I-II) and mild flu-like symp-
toms were observed in two patients (no. 2, UH, no. 10, LA) with
temperatures up to 39°C, lasting up to 24 h post immunization.
DISCUSSION
Previous animal studies indicate that a potent protective immune
response can be generated in vivo using cytokine gene-modified
tumour cells (reviewed by Colombo and Forni, 1994; Vieweg and
Gilboa, 1995). The possible mechanisms by which cytokine-
modified tumour cells may function as vaccines have been
reviewed elsewhere (Finke et al, 1997). Active immunotherapy of
certain human cancers, including malignant melanoma, using
cytokine gene modification ofautologous tumour cells is currently
being tested in a number of clinical trials (reviewed by Pardoll,
1995). We report here on the results ofthe first clinical phase I trial
using autologous, IL-7 gene-modified tumour cells for the treat-
ment of ten patients with advanced metastatic melanoma. This
pilot study demonstrates the feasibility and safety as well as the
lack of toxicity of such an approach. Although five patients
showed stable disease and two mixed response for some time, no
major clinical response (CR, PR) was achieved.
However, in three of seven patients, immunological monitoring
suggested an increase of anti-melanoma lytic clones (up to 28-
fold) in the peripheral blood, comparing the pre- to post vaccina-
tion status. Frequency analysis of tumour-reactive lymphocytes
has been used by others, with good results 2 weeks after vaccina-
tion (Schmidt-Wolf and Schmidt-Wolf, 1995). Whether or not the
immunological changes observed are caused by the IL-7 transfec-
tion could notbe tested in this initial phase I study. Ethical require-
ments did not allow a control group with non- or mock-transfected
tumour cells at this point. Nevertheless, experiments using human
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melanoma cell lines transfected with the IL-7 gene demonstrated
an advantage of transfected melanoma cells similar to non-
transfected cells plus the addition of exogenous IL-7 for the
generation of cytotoxic lymphocytes in vitro (Miller et al, 1993).
Furthermore, proliferation and cytotoxicity of the T cells could be
driven by paracrine IL-7 even in concentrations secreted by the
administered vaccines (Finke et al, 1997). The exact dosage of IL-
7 needed to mediate an anti-tumour effect in vivo is presently not
clear. Hock et al (1991 ) used 4 x 106 tumour cells secreting around
20 ng ml-' for tumour transplantation onto mice, however this situ-
ation is not mimicking the human situation with a widely dissemi-
nated disease at the start of treatment. IL-7 has also been reported
to be able to break tolerance oftolerized and anergic T cells (Filion
et al, 1995). Nevertheless, no sign of inflammation has been
observed at the vaccination sites in our clinical study.
In this clinical trial, immunologically responsive patients were
characterized by a Kamofsky index above 70 and a marked response
against recall antigens (Multitest Merieux) before vaccination.
Furthermore, they received a large number ofautologous melanoma
cells (> 107 cells) secreting a high amount of IL-7 (> 5000 pg).
Whether Kamofsky index, Multitest reactivity or cell number used
for vaccination are relevant is difficult to assess because ofthe small
number of patients treated. Interestingly, the melanoma cells from
two ofthree immunologically responsive patients secreted only low
amounts of the immunosuppressive cytokine TGF-PI in a group of
seven investigated patients. Preliminary characterization ofcytolytic
T cell lines generated after vaccination suggests that not the
commonly known melanoma-associated antigens, such as MAGE-
1, MAGE-3, tyrosinase, Melan-A or gpO00, are recognized in the
context of HLA-A2, but possibly so far unknown melanoma
antigens presented by HLA-B or -C alleles.
In conclusion, vaccination with gene-modified tumour cells
seems to be feasible and well tolerated. However, autologous
tumour vaccines, which should have all relevant tumour antigens
for the individual patient and pose no problems regarding HLA
incompatibilities, are very labour, cost and time intensive to
prepare. A major problem in the preparation of autologous tumour
cell vaccines is the long latency period that was (sometimes)
needed to expand the tumour cells in vitro; several of the patients
substantially worsened in their clinical performance status.
Furthermore, adjuvant immunization, which is more likely to alter
the clinical course in tumour patients, is severely hampered by the
requirement to obtain autologous tumour tissue. Therefore, besides
using autologous tumour cells for gene transfer and vaccination,
some clinical trials are under way using allogeneic tumour cell lines
for vaccination (Gansbacher et al, 1992; Schmidt-Wolf and
Schmidt-Wolf, 1995). This approach requires comparably less
extensive cell preparations and allows for easier standardization,
although the benefit of a strong allogeneic reaction in such an
immunization approach is not sufficiently evaluated. Particularly,
the loss of HLA alleles on the tumour cells, as observed in one of
our patients (and two other patients not included in this study), and
the need for a number of well-defined tumour antigens to be
expressed favour, at this point, the allogeneic immunization.
Vaccination trials using allogeneic, well-defined (regarding tumour
antigens, secretion of immunosuppressive mediators and expres-
sion of HLA molecules) tumour cell vaccines that can use easier-
to-standardize immunological detection assays for a number of
defined tumour antigens should allow the evaluation of the poten-
tial and the limits ofthis new treatment modality in the near future.
ACKNOWLEDGEMENTS
This work was supported by the DFG (Scha 422/3-2, Scha 422/5-1
and Scha 422/6-1) and by the Centrum Somatische Genetherapie
e.V. DS is a Heisenberg-Fellow of the DFG. The authors are
grateful to LJ Old (Ludwig Institute for Cancer Research, NY,
USA) for providing the human melanoma cell lines. The active
support of Professor Gollnick, Madgeburg, and the excellent tech-
nical assistance of Mrs Antje Sucker, Helga Kemmer and Iris
Ziglowski are gratefully acknowledged.
ABBREVIATIONS
IL, interleukin; LAK, lymphokine-activated killer; PBL, periph-
eral blood lymphocytes; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide; NK, natural killer; LDH, lactate
dehydrogenase, DTH, delayed-type hypersensitivity; DMSO,
dimethyl sulphoxide; PBS, phosphate-buffered saline; PBMCs,
peripheral blood mononuclear cells; LDA, limiting dilution
analysis; APC, antigen-presenting cells; FCS, fetal calf serum;
CTL, cytolytic T lymphocyte
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